<DOC>
	<DOCNO>NCT02871869</DOCNO>
	<brief_summary>Diffuse large B cell lymphoma ( DLBCL ) , common subtype non-Hodgkin lymphoma ( NHL ) , great heterogeneity clinical manifestation , histological morphology prognosis . R-CHOP Protocol ( Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone ) gold therapeutic criterion patient NHL , also use first-line treatment patient DLBCL . After treatment , 50％～60％of patient DLBCL receive complete remission ( CR ) , 30％～40％ recurrent 10 % never cure due initial secondary drug tolerance . This study aim explore whether Cinobufacini Tablets synergistic effect treatment DLBCL , whether action close association positive expression Na+/K+-ATPase α3 , observe rate adverse reaction induce Cinobufacini Tablets treatment .</brief_summary>
	<brief_title>Cinobufacini Tablets Combined With Chemotherapeutic Protocol Treatment Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>Diffuse large B cell lymphoma ( DLBCL ) , common subtype non-Hodgkin lymphoma ( NHL ) , account 30％～40％ adult NHL , great heterogeneity clinical manifestation , histological morphology prognosis . R-CHOP Protocol ( Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone ) gold therapeutic criterion patient NHL , also use first-line treatment patient DLBCL . After treatment , 50％～60％of patient DLBCL receive complete remission ( CR ) , 30％～40％ recurrent 10 % never cure due initial secondary drug tolerance . The study Tao Wu et al domestic show cinobufacini combine CHOP protocol excellent efficacy treatment NHL , response rate reach 91.7 % , adverse reaction mild tolerable , whereas response rate single CHOP 62.5 % . In clinical practice study , also find patient recurrent DLBCL NHL also shrink disappeared tumor survival time 2 year single administration cinobufacini tablets 3~6 month follow withdrawal chemotherapy . This study aim explore whether Cinobufacini Tablets synergistic effect treatment DLBCL , whether action close association positive expression Na+/K+-ATPase α3 , observe rate adverse reaction induce Cinobufacini Tablets treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Bufanolides</mesh_term>
	<criteria>For control trial group A : Patients aged 1870 year old ; Patients eastern Collaborative Oncology Group ( ECOG ) performance status ( PS ) score : 0～3 point ; International prognostic index ( IPI ) : ≤3 point ; Patients diagnose diffuse large B cell lymphoma ( DLBCL ) initial treatment histopathology ; Patients 1 measurable nidus ( common CT MRI scan diameter ≥ 20 mm , spiral CT scan diameter ≥ 10 mm ) ; Patients without dysfunction important organ , normal blood routine , hepatorenal function cardiac function . White blood cell count ( WBC ) ≥4.0×109/L , neutrophil count ≥1.5×109/L ; platelet ( PLT ) count ≥100×109/L ; hemoglobin ( HGB ) ≥95g/L ; serum bilirubin ( Bil ) ≤1.5 fold upper limit normal value , alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) ≤2 fold upper limit normal value , serum creatinine ( Scr ) ≤1.5mg/dl ; Patients expect survival time＞3 month ; Patients well inform study sign informed consent form . Patients receive administration Rituximab . Patients conform criterion ; Patients receive anticancer therapy ; Patients DLBCL affect primary breast gland , lung , testis , bone , periorbit , perispine , central nerve system bone marrow ; Patients double expression , double strike , trinary expression trinary strike CD5+ ; Patients complicate nonDLBCL primary malignant tumor ; Patients poor compliance family ; Patients one follow condition : uncontrolled metastatic nidi central nerve system , dysfunction important organ severe cardiac disease like congestive heart failure , uncontrollable arrhythmia , angina pectoris need longterm drug administration , valvular heart disease , myocardial infarction refractory hypertension , pregnancy lactation , chronic infectious wound , history uncontrollable psychological disease . Patients previous history treatment Cinobufacini Tablets . For control trial group B Patients age 1870 year old ; Patients eastern Collaborative Oncology Group ( ECOG ) performance status ( PS ) score : 0～3 point ; International prognostic index ( IPI ) : ≤3 point ; Patients diagnose diffuse large B cell lymphoma ( DLBCL ) initial treatment histopathology ; Patients 1 measurable nidus ( common CT MRI scan diameter ≥ 20 mm , spiral CT scan diameter ≥ 10 mm ) ; Patients without dysfunction important organ , normal blood routine , hepatorenal function cardiac function . White blood cell count ( WBC ) ≥4.0×109/L , neutrophil count ≥1.5×109/L ; platelet ( PLT ) count ≥100×109/L ; hemoglobin ( HGB ) ≥95g/L ; serum bilirubin ( Bil ) ≤1.5 fold upper limit normal value , alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) ≤2 fold upper limit normal value , serum creatinine ( Scr ) ≤1.5mg/dl ; Patients expect survival time＞3 month ; Patients well inform study sign informed consent form . Patients receive administration Rituximab . Patients conform criterion ; Patients receive anticancer therapy ; Patients DLBCL affect primary breast gland , lung , testis , bone , periorbit , perispine , central nerve system bone marrow ; Patients double expression , double strike , trinary expression trinary strike CD5+ ; Patients complicate nonDLBCL primary malignant tumor ; Patients poor compliance family ; Patients one follow condition : uncontrolled metastatic nidi central nerve system , dysfunction important organ severe cardiac disease like congestive heart failure , uncontrollable arrhythmia , angina pectoris need longterm drug administration , valvular heart disease , myocardial infarction refractory hypertension , pregnancy lactation , chronic infectious wound , history uncontrollable psychological disease . Patients previous history treatment Cinobufacini Tablets .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cinobufacini Tablets</keyword>
	<keyword>CHOP protocol</keyword>
</DOC>